Advertisements

Stocking Stuffers

 

Immunovaccine Inc. (IMV:CA) Stock Quote

Detailed Quote for IMV Inc. (IMV:CA)
$ 3.71   -0.02 (-0.54%) Volume: 42.09k 3:59 PM EST Dec 6, 2019
Today 5d 1m 3m 1y more
Last Price
3.71
Change $
0.02
Change %
0.54%
Tick
  
Bid
3.63
Bid Size
500
Ask
3.81
Ask Size
500
Open
3.75
High
3.84
Low
3.56
Prev Close
3.73
Last Trade
12/06/19
Volume
42.09k
52 Wk Hi
7.92999982
52 Wk Low
2.76999998
Market Cap
187.84m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
50,630,875
EPS (TTM)
-0.560000002
PE Ratio
N/A
Exchange
TSX
News and Media for IMV Inc. (IMV:CA)
Sector News | Topic News
News for IMV Inc. (IMV:CA)
Sun, Dec 08, 2019
12:05 PM Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting - Business Wire
Wed, Nov 27, 2019
7:05 AM IMV to Participate at Two Upcoming Investor Conferences - Business Wire
Fri, Nov 08, 2019
7:05 AM IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update - Business Wire
Wed, Nov 06, 2019
9:01 AM Updated Results from Phase 2 SPiReL Study Evaluating IMV's DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting - Business Wire
Tue, Nov 05, 2019
8:01 AM IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting - Business Wire
Wed, Oct 30, 2019
7:05 AM IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer - Business Wire
Tue, Oct 29, 2019
7:05 AM IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019 - Business Wire
Wed, Oct 16, 2019
10:01 AM / C O R R E C T I O N From Source - IMV Inc / - Business Wire
Fri, Oct 11, 2019
7:05 AM IMV Inc. to Present at Upcoming Investor Conference - Business Wire
Mon, Sep 30, 2019
3:00 AM Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019 - Business Wire
Mon, Sep 23, 2019
7:05 AM Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019 - Business Wire
Wed, Sep 04, 2019
7:05 AM IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation - Business Wire
Thu, Aug 22, 2019
7:05 AM IMV Inc. to Present at Upcoming Investor Conferences - Business Wire
Thu, Aug 08, 2019
5:05 PM IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update - Business Wire
Fri, Jul 26, 2019
4:00 PM IMV Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference - Business Wire
Thu, Jul 25, 2019
3:22 PM IMV Inc. to Announce Second Quarter 2019 Results and Host a Conference Call and Webcast on August 9, 2019 - Business Wire
Thu, Jun 13, 2019
5:08 PM IMV Inc. to Present at Two Upcoming Investor Conferences - Business Wire
Wed, Jun 12, 2019
7:05 AM New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with Merck's Keytruda in Patients with DLBCL - Business Wire
Tue, Jun 04, 2019
7:05 AM IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019 - Business Wire
Sat, Jun 01, 2019
2:15 PM IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival - Business Wire
More News for IMV:CA >>

Tags for Immunovaccine Inc.

Research stocks or mutual funds related to Immunovaccine Inc. by keywords or tags. Find companies that have a similar focus to IMV:CA. The keywords below have been associated to IMV:CA by either user submission or electronic means.